Ratings for the strength of the recommendations (Strong, Fair, Weak, Consensus, Insufficient Evidence), conclusion grades (I-V), and statement labels (Conditional versus Imperative) are defined at the end of the "Major Recommendations" field.
Gestational Diabetes Mellitus (GDM): Screening for GDM
GDM: Screening for GDM
All pregnant women should be screened for GDM and/or impaired glucose tolerance (IGT); however, depending on level of risk, timing of screening will differ. Research indicates the similarities between GDM and IGT, and both are associated with increased risks of poor maternal/neonatal outcomes if left untreated.
Strong, Imperative
Recommendation Strength Rationale
- Conclusion Statements were Grades I and II
GDM: Pregnant Women at Risk for GDM
GDM: Pregnant Women at Risk for GDM
For pregnant women at average or high risk for GDM, the registered dietitian (RD) should monitor weight gain, nutritional intake and physical activity. Research indicates that obesity, excessive weight gain prior to pregnancy and increased saturated fat intake are associated with the development of glucose abnormalities in pregnancy and increased risk of gestational diabetes. In addition, regular physical activity during pregnancy reduces the risk of GDM.
Weak, Conditional
Recommendation Strength Rationale
- Conclusion Statements were Grade II
GDM: MNT for Pregnant Women with IGT or GDM
GDM: MNT for Women with GDM
The RD should initiate MNT within one week after diagnosis of GDM, and include a minimum of three nutrition visits. Research indicates that MNT results in improved maternal and neonatal outcomes, especially when diagnosed and treated early.
Strong, Imperative
GDM: MNT for Pregnant Women with IGT
For women with IGT during pregnancy, the RD should initiate the same recommendations of MNT as those for GDM. Research indicates that IGT and GDM carry similar risks of adverse outcomes.
Strong, Imperative
Recommendation Strength Rationale
- Conclusion Statements were Grades I and II
GDM: Assessment of Food Intake, Physical Activity and Medications
GDM: Assess Food Intake, Physical Activity and Medications
The RD should assess dietary intake and physical activity of pregnant women, including those with GDM. Evaluation of a pregnant woman's dietary pattern, augmented by questions about medications, special concerns, conditions, and/or food preferences that might affect her dietary adequacy or needs, provides the basis for MNT.
Consensus, Imperative
Recommendation Strength Rationale
The American Dietetic Association (ADA) Gestational Diabetes Mellitus Expert Work Group concurs with the clinical recommendations from the Committee on Nutritional Status During Pregnancy and Lactation, Institute of Medicine.
GDM: Assessment of Body Mass Index (BMI) and Weight Gain
GDM: Assessment of BMI and Weight Gain
The RD should assess body mass index (based on actual or estimated prepregnancy weight) as a baseline to determine recommended weight gain in pregnant women, including those with GDM. BMI is a better indicator of maternal nutritional status than is weight alone.
Consensus, Imperative
Recommendation Strength Rationale
The ADA Gestational Diabetes Mellitus Expert Work Group concurs with the clinical recommendations from the Committee on Nutritional Status During Pregnancy and Lactation, Institute of Medicine.
GDM: Caloric Intake
GDM: Caloric Intake for Normal and Underweight Women
The RD should encourage normal and underweight women with GDM to consume adequate calories to promote appropriate weight gain while preventing hyperglycemia and ketonuria, with guidance from the Dietary Reference Intakes (DRI) for pregnant women. Research indicates that low or inadequate weight gain during pregnancy is associated with an increased risk of preterm delivery, regardless of prepregnancy BMI levels.
Fair, Conditional
GDM: Caloric Intake for Overweight/Obese Women with GDM
Since weight loss in pregnancy is not recommended, the RD should encourage a modest energy restriction to slow weight gain in women with GDM who are also overweight/obese. Caloric restriction (~70% of the DRI for pregnant women) results in considerable slowing of maternal weight gain in obese women with GDM, without causing maternal or fetal compromise and/or ketonuria.
Fair, Conditional
Recommendation Strength Rationale
- Conclusion Statements were Grades II and III
GDM: Macronutrient and Micronutrient Intake
GDM: Carbohydrate Intake
The RD should encourage pregnant women, including those with GDM, to consume a minimum of 175 g of carbohydrate per day based on the DRI for pregnant women for provision of glucose to the fetal brain and to prevent ketosis. Total carbohydrate intake should be less than 45% of energy to prevent hyperglycemia in women with GDM. Carbohydrate intake affects postprandial blood glucose levels; increased postprandial blood glucose levels are associated with increased incidence of large-for-gestational age infants and increased rate of Cesarean sections. Research is limited regarding fiber intake and glycemic index in women with GDM.
Fair, Imperative
GDM: Protein and Fat Intake
The RD should encourage pregnant women, including those with GDM, to consume adequate protein and fat based on the DRI for pregnant women. Research is limited regarding protein and fat intake in women with GDM.
Fair, Imperative
GDM: Vitamin and Mineral Supplementation
If usual dietary intake does not meet the DRI for pregnant women, including those with GDM, the RD should encourage vitamin and mineral supplementation to prevent nutritional deficiencies.
Consensus, Conditional
Recommendation Strength Rationale
- Conclusion Statement was Grade II
GDM: Physical Activity
GDM: Physical Activity
Unless contraindicated, the RD should encourage women with GDM to participate in physical activity for 30 minutes per day for a minimum of three times per week. Research indicates that regular physical activity during pregnancy aids with improved glycemic control and reduces the common discomforts of pregnancy, without a negative effect on maternal or neonatal outcomes.
Fair, Conditional
Recommendation Strength Rationale
- Conclusion Statement was Grade II
GDM: Blood Glucose Monitoring and Ketone Testing
GDM: Blood Glucose Monitoring
The RD should advise women with GDM to monitor their blood glucose, including fasting and postprandial levels. Several studies report a correlation between elevated fasting and postprandial blood glucose values with poor maternal and neonatal outcomes.
Fair, Imperative
GDM: Ketone Testing
The RD should recommend ketone testing for women with GDM who have insufficient calorie and/or carbohydrate intake and/or weight loss. Two of three studies regarding ketonemia and ketonuria with poor metabolic control during a diabetic pregnancy report a positive association with lower intelligence quotient (IQ) in offspring.
Fair, Conditional
Recommendation Strength Rationale
- Conclusion Statement was Grade II
GDM: Use of Non-Nutritive Sweeteners
GDM: Use of Non-Nutritive Sweeteners
If women with GDM choose to consume products containing non-nutritive sweeteners, the RD should inform them that only U.S. Food and Drug Administration (FDA)-approved non-nutritive sweeteners should be consumed and that moderation is encouraged. Research in this area is extremely limited.
Consensus, Conditional
Recommendation Strength Rationale
- Conclusion Statement was Grade IV
GDM: Promotion of Breastfeeding
GDM: Promotion of Breastfeeding
Unless contraindicated, the RD should encourage breastfeeding in women with GDM. Research indicates that even short duration of breastfeeding results in long-term improvements in glucose metabolism and may also reduce the risk of type 2 diabetes in children.
Weak, Conditional
Recommendation Strength Rationale
- Conclusion Statement was Grade III
GDM: Alcohol Consumption
GDM: Alcohol Consumption
The RD should advise pregnant women, including those with GDM, to avoid the consumption of alcohol, including alcohol used in cooking. No amount of alcohol consumption can be considered safe during pregnancy. Alcohol use during pregnancy increases the risk of alcohol-related birth defects, including growth deficiencies, facial abnormalities, central nervous system impairment, behavioral disorders, and impaired intellectual development.
Consensus, Imperative
Recommendation Strength Rationale
The ADA Gestational Diabetes Mellitus Expert Work Group concurs with the clinical recommendations from the National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control, Department of Health and Human Services, in coordination with the National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect.
GDM: Pharmacological Therapy for Treatment of GDM
GDM: Pharmacological Therapy for Treatment of GDM
When optimal blood glucose levels have not been maintained with MNT and/or the rate of fetal growth is excessive, the RD should advise the healthcare team about the initiation of pharmacological therapy for treatment of women with GDM. Research indicates that pharmacological therapy, such as the use of insulin, insulin analogs and glyburide, improves glycemic control and reduces the incidence of poor maternal and neonatal outcomes.
Strong, Conditional
Recommendation Strength Rationale
- Conclusion Statement was Grade II
GDM: Monitor and Evaluate MNT Effectiveness
GDM: Monitor and Evaluate MNT Effectiveness
The RD should monitor and evaluate blood glucose, weight, food intake, physical activity and pharmacological therapy (if indicated) in women with GDM at each visit. Research indicates that MNT results in improved maternal and neonatal outcomes.
Strong, Imperative
Recommendation Strength Rationale
- Conclusion Statement was Grade II
GDM: Prevention of GDM Recurrence/Type 2 Diabetes
GDM: Weight Loss after Delivery
For women with GDM who are overweight/obese or with above recommended weight gain during pregnancy, the RD should advise weight loss after delivery. Research indicates that the risks of recurrent GDM or development of type 2 diabetes can be reduced with weight loss.
Strong, Conditional
Recommendation Strength Rationale
- Conclusion Statements were Grade I
Note: The recommendations listed below were originally developed for other ADA evidence-based nutrition practice guidelines, but have been integrated into the Gestational Diabetes Evidence-based Nutrition Practice Guideline and may provide additional guidance for the practitioner.
Diabetes Mellitus (DM): Fiber and Diabetes
DM: Fiber Intake and Glycemia
Recommendations for fiber intake for people with diabetes are similar to the recommendations for the general public (DRI: 14 g per 1000 kcal). While diets containing 44 to 50 g of fiber daily are reported to improve glycemia, more usual fiber intakes (up to 24 g daily) have not shown beneficial effects on glycemia. It is unknown if free-living individuals can daily consume the amount of fiber needed to improve glycemia.
Strong, Imperative
DM: Fiber Intake and Cholesterol
Include foods containing 25 to 30 g of fiber per day, with special emphasis on soluble fiber sources (7 to 13 g). Diets high in total and soluble fiber, as part of cardioprotective nutrition therapy, can further reduce total cholesterol by 2 to 3% and low-density lipoprotein (LDL) cholesterol up to 7%.
Strong, Imperative
Recommendation Strength Rationale
- Conclusion Statement for Fiber and Diabetes is Grade I
- Conclusion Statements for Fiber and congestive heart disease (CHD) were Grades I, II and III
(DM): Carbohydrate
DM: Carbohydrate Intake Consistency
In persons on either MNT alone, glucose-lowering medications or fixed insulin doses, meal and snack carbohydrate intake should be kept consistent on a day-to-day basis. Consistency in carbohydrate intake results in improved glycemic control.
Strong, Conditional
DM: Carbohydrate Intake and Insulin Dose Adjustment
In persons with type 1 or type 2 diabetes who adjust their mealtime insulin doses or who are on insulin pump therapy, insulin doses should be adjusted to match carbohydrate intake (insulin-to-carbohydrate ratio). This can be accomplished by comprehensive nutrition education and counseling on interpretation of blood glucose patterns, nutrition-related medication management and collaboration with the healthcare team. Adjusting insulin dose based on planned carbohydrate intake improves glycemic control and quality of life without any adverse effects.
Strong, Conditional
Recommendation Strength Rationale
- Conclusion Statement was Grade I
DM: Glycemic Index and Diabetes
DM: Glycemic Index (GI)
If the use of glycemic index is proposed as a method of meal planning, the RD should advise on the conflicting evidence of effectiveness of this strategy. Studies comparing high versus low GI diets report mixed effects on A1C.
Fair, Conditional
Recommendation Strength Rationale
- Conclusion statement was Grade II
Definitions:
Conditional versus Imperative Recommendations
Recommendations can be worded as conditional or imperative statements. Conditional statements clearly define a specific situation, while imperative statements are broadly applicable to the target population without restraints on their pertinence. More specifically, a conditional recommendation can be stated in if/then terminology (e.g., if an individual does not eat food sources of omega-3 fatty acids, then 1 g of EPA and DHA omega-3 fatty acid supplements may be recommended for secondary prevention).
In contrast, imperative recommendations "require," "must," or "should achieve certain goals," but do not contain conditional text that would limit their applicability to specified circumstances. (e.g., portion control should be included as part of a comprehensive weight management program. Portion control at meals and snacks results in reduced energy intake and weight loss).
Level of Evidence
Strength of Evidence Elements |
Grade I
Good/Strong |
Grade II
Fair |
Grade III
Limited/Weak |
Grade IV
Expert Opinion Only |
Grade V
Grade Not Assignable |
Quality
- Scientific rigor/validity
- Considers design and execution
|
Studies of strong design for question
Free from design flaws, bias and execution problems |
Studies of strong design for question with minor methodological concerns
OR
Only studies of weaker study design for question |
Studies of weak design for answering the question
OR
Inconclusive findings due to design flaws, bias or execution problems |
No studies available
Conclusion based on usual practice, expert consensus, clinical experience, opinion, or extrapolation from basic research |
No evidence that pertains to question being addressed |
Consistency
Of findings across studies |
Findings generally consistent in direction and size of effect or degree of association, and statistical significance with minor exceptions at most |
Inconsistency among results of studies with strong design
OR
Consistency with minor exceptions across studies of weaker designs |
Unexplained inconsistency among results from different studies
OR
Single study unconfirmed by other studies |
Conclusion supported solely by statements of informed nutrition or medical commentators |
NA |
Quantity
- Number of studies
- Number of subjects in studies
|
One to several good quality studies
Large number of subjects studies
Studies with negative results having sufficiently large sample size for adequate statistical power |
Several studies by independent investigators
Doubts about adequacy of sample size to avoid Type I and Type II error |
Limited number of studies
Low number of subjects studies and/or inadequate sample size within studies |
Unsubstantiated by published studies |
Relevant studies have not been done |
Clinical Impact
- Importance of studies outcomes
- Magnitude of effect
|
Studied outcome relates directly to the question
Size of effect is clinically meaningful
Significant (statistical) difference is large |
Some doubt about the statistical or clinical significance of effect |
Studies outcome is an intermediate outcome or surrogate for the true outcome of interest
OR
Size of effect is small or lacks statistical and/or clinical significance |
Objective data unavailable |
Indicates area for future research |
Generalizability
To population of interest |
Studied population, intervention and outcomes are free from serious doubts about generalizability |
Minor doubts about generalizability |
Serious doubts about generalizability due to narrow or different study population, intervention or outcomes studied |
Generalizability limited to scope of experience |
NA |
This grading system was based on the grading system from: Greer N, Mosser G, Logan G, Wagstrom Halaas G. A practical approach to evidence grading. Jt Comm. J Qual Improv. 2000; 26:700-712. In September 2004, The ADA Research Committee modified the grading system to this current version.
Criteria for Recommendation Rating
Statement Rating |
Definition |
Implication for Practice |
Strong |
A Strong recommendation means that the workgroup believes that the benefits of the recommended approach clearly exceed the harms (or that the harms clearly exceed the benefits in the case of a strong negative recommendation), and that the quality of the supporting evidence is excellent/good (grade I or II)*. In some clearly identified circumstances, strong recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms. |
Practitioners should follow a Strong recommendation unless a clear and compelling rationale for an alternative approach is present. |
Fair |
A Fair recommendation means that the workgroup believes that the benefits exceed the harms (or that the harms clearly exceed the benefits in the case of a negative recommendation), but the quality of evidence is not as strong (grade II or III)*. In some clearly identified circumstances, recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits outweigh the harms. |
Practitioners should generally follow a Fair recommendation but remain alert to new information and be sensitive to patient preferences. |
Weak |
A Weak recommendation means that the quality of evidence that exists is suspect or that well-done studies (grade I, II, or III)* show little clear advantage to one approach versus another. |
Practitioners should be cautious in deciding whether to follow a recommendation classified as Weak, and should exercise judgment and be alert to emerging publications that report evidence. Patient preference should have a substantial influencing role. |
Consensus |
A Consensus recommendation means that Expert opinion (grade IV)* supports the guideline recommendation even though the available scientific evidence did not present consistent results, or controlled trials were lacking. |
Practitioners should be flexible in deciding whether to follow a recommendation classified Consensus, although they may set boundaries on alternatives. Patient preference should have a substantial influencing role. |
Insufficient Evidence |
An Insufficient Evidence recommendation means that there is both a lack of pertinent evidence (grade V)* and/or an unclear balance between benefits and harms. |
Practitioners should feel little constraint in deciding whether to follow a recommendation labeled as Insufficient Evidence and should exercise judgment and be alert to emerging publications that report evidence that clarifies the balance of benefit versus harm. Patient preference should have a substantial influencing role. |
*Conclusion statements are assigned a grade based on the strength of the evidence. Grade I is good; grade II, fair; grade III, limited; grade IV signifies expert opinion only and grade V indicates that a grade is not assignable because there is no evidence to support or refute the conclusion. The evidence and these grades are considered when assigning a rating (Strong, Fair, Weak, Consensus, Insufficient Evidence - see chart above) to a recommendation.
Adapted by the American Dietetic Association from the American Academy of Pediatrics, Classifying Recommendations for Clinical Practice Guideline, Pediatrics. 2004;114;874-877.